3 minute read
regulatory lensLorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim Construction starts on the veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate Medicines Manufacturing
CPI has announced the start of construction at the Medicines Manufacturing Innovation Centre in Renfrewshire, Scotland.
The new technology and innovation centre is set to become a unique and world-leading facility offering transformative solutions in small molecule and pharmaceutical manufacturing. It will accelerate the development and industrialisation of next-generation medicines, manufacturing innovations and maximise technology opportunities within the medicines supply chain. Industry, academia, healthcare providers and
regulators will work collaboratively Companies of all sizes will be able to use systems higher than ever before. However, within a GMP environment to address the facility to evaluate, test and prototype for a highly regulated industry, innovation is industry challenges and de-risk new processes using an array of advanced risky and potentially expensive. This facility will technologies, providing a clear pathway Industry 4.0 manufacturing technologies, enable close collaboration between industry, for their widespread adoption within the including continuous, digital and autonomous government and academia and will be a gamepharmaceutical industry. manufacturing. The utilisation of next- changer, resulting in faster industrialisation and generation technology will enable more implementation of exciting new opportunities.” The Medicines Manufacturing Innovation efficient drug production to protect future Centre is a collaboration between CPI, the University of Strathclyde and founding industry partners GSK and AstraZeneca, with funding provided by Scottish Enterprise and UK Research and Innovation. The Centre has recently agreed partnerships with four leading technology companies to further strengthen the range of expertise in the collaboration. generations by bringing new medicines to market safely and quickly. The facility is due for completion in late 2021 and will be operational in early 2022. It is expected to eventually house over 80 staff in both technical and non-technical roles. Professor Sir Jim McDonald, Principal Dave Tudor, Managing Director of the Medicines Manufacturing Innovation Centre, Quality and Biologics at CPI, said: “We are thrilled to be starting the construction of this new, collaborative centre. The consortium is already working together on several ambitious projects with the aim to de-risk disruptive technology that can lower the cost of drug development. and Vice-Chancellor of the University of Live projects include a digitally-twinned Strathclyde, said: “As strategic partners in the continuous direct compression platform to Medicines Manufacturing Innovation Centre, increase the productivity of drug product the University of Strathclyde is utilising its manufacture, and an automated platform to
The facility will translate, at industrial and commercial scale, novel techniques for producing patient-centric medicines, including research, innovation and internationallyleading experience and expertise in advanced medicines manufacturing to meet the biggest health challenges facing our world. We are enable just-in-time supply for clinical trials which will drastically cut lead times. We look forward to bringing that technology and cross-sector expertise to these new facilities.” real-time release of drugs and integrated process analytics to drive the transformation of medicines manufacturing. These technologies will enable a reduction in quantities of the materials currently required in process development; accelerate timelines to achieve just-in-time, right-first-time and real-timerelease manufacturing principles; and ultimately accelerate access of affordable medicines for healthcare providers and patients. delighted to be working in collaboration with our partners across industry, academia, government and healthcare to accelerate and transform the medicines manufacturing process. We are excited to see construction begin on what will be a distinctive and important asset to the Glasgow City region and to Scotland.” Jon-Paul Sherlock, Technology Strategy Lead at AstraZeneca, commented: “Manufacturing innovation is critical to future pharmaceutical supply chains. Molecules are more complex, development times shorter and the Frank Millar, CEO at CPI, added: “Ageing populations, the increasing cost of drug development, and resource constraints impeding the adoption of emergent technologies are just some of the challenges facing the pharmaceutical industry today. The increasing financial burden on the healthcare system as a whole has led to a pressing need for more cost-effective medication. By connecting the dots between academia, government, industry and healthcare providers within this state-of-the-art centre, we can address these issues and transform the pharmaceutical supply expectations of patients and healthcare chain for the future.”
